PMID- 10561247
OWN - NLM
STAT- MEDLINE
DCOM- 20000607
LR  - 20170210
IS  - 0732-183X (Print)
IS  - 0732-183X (Linking)
VI  - 17
IP  - 7
DP  - 1999 Jul
TI  - Comparison of fluorescence in situ hybridization and immunohistochemistry for the 
      evaluation of HER-2/neu in breast cancer.
PG  - 1974-82
AB  - PURPOSE: To compare fluorescence in situ hybridization (FISH) and 
      immunohistochemistry (IHC) in the determination of HER-2/neu status of breast 
      cancers. MATERIALS AND METHODS: FISH and IHC for HER-2/neu were performed on 
      formalin-fixed paraffin sections of 100 consecutive invasive breast cancers. FISH 
      was performed at Beth Israel Deaconess Medical Center, Boston, MA, using the 
      Oncor/Ventana INFORM kit (Ventana Medical Systems, Tucson, AZ; formerly sold by 
      Oncor, Inc, Gaithersburg, MD) in a laboratory certified as proficient in this 
      procedure. IHC was performed at PhenoPath Laboratories, Seattle, WA, using a 
      polyclonal antibody to the HER-2/neu protein. FISH and IHC were analyzed in a 
      blinded fashion, and the results were then compared. Procedure and interpretation 
      times and reagent costs for FISH and IHC were also compared. RESULTS: HER-2/neu 
      was amplified by FISH in 26% of cases, and 23% were HER-2/neu-positive by IHC. 
      FISH and IHC were both assessable in 90 cases. Concordance between FISH and IHC 
      results was seen in 82 of these cases (91%, P <.001). The FISH procedure required 
      more technologist time and more interpretation time per case for the pathologist 
      than IHC. Reagent costs were substantially higher for FISH than for IHC. 
      CONCLUSION: There is a high level of correlation between FISH and IHC in the 
      evaluation of HER-2/neu status of breast cancers using formalin-fixed 
      paraffin-embedded specimens. Although the choice of which assay to use should be 
      left for individual laboratories to make based on technical and economic 
      considerations, our results may make it difficult to justify the routine use of 
      FISH for determination of HER-2/neu status in breast cancer.
FAU - Jacobs, T W
AU  - Jacobs TW
AD  - Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical 
      School, Boston, MA 02215, USA.
FAU - Gown, A M
AU  - Gown AM
FAU - Yaziji, H
AU  - Yaziji H
FAU - Barnes, M J
AU  - Barnes MJ
FAU - Schnitt, S J
AU  - Schnitt SJ
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - J Clin Oncol
JT  - Journal of clinical oncology : official journal of the American Society of 
      Clinical Oncology
JID - 8309333
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
CIN - J Clin Oncol. 1999 Nov;17(11):3690-2. PMID: 10550171
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Breast Neoplasms/*pathology
MH  - Cohort Studies
MH  - Female
MH  - Health Care Costs
MH  - Humans
MH  - *Immunohistochemistry/economics
MH  - *In Situ Hybridization, Fluorescence/economics
MH  - Middle Aged
MH  - Receptor, ErbB-2/*analysis
MH  - Sensitivity and Specificity
MH  - Statistics, Nonparametric
MH  - Time Factors
EDAT- 1999/11/24 09:00
MHDA- 2000/06/10 09:00
CRDT- 1999/11/24 09:00
PHST- 1999/11/24 09:00 [pubmed]
PHST- 2000/06/10 09:00 [medline]
PHST- 1999/11/24 09:00 [entrez]
AID - 10.1200/JCO.1999.17.7.1974 [doi]
PST - ppublish
SO  - J Clin Oncol. 1999 Jul;17(7):1974-82. doi: 10.1200/JCO.1999.17.7.1974.